SUPLPLEMENTARY MATERIAL TO

**Chemical composition and antioxidant activity of *Astragalus monspessulanus* L.**

**growing in semiarid areas of Algeria**

SAWSEN BOUREZZANE1, HAMADA HABA1, CHRISTOPHE LONG2and

MOHAMMED BENKHALED1\*

*1Laboratory of Chemistry and EnvironmentalChemistry (L.C.C.E), Department ofChemistry, Faculty of Sciences, Batna-1University, Algeria*

*2USR 3388 CNRS-Pierre Fabre, 3 Avenue Hubert Curien BP 13562, 31035 Toulouse, France*

ISOLATION OF THE FRACTIONS

 7 g of ethyl acetate extract were subjected to vacuum liquid chromatography VLC (50 mm × 50 mm; fractions of 100 ml) on RP-18 using a gradient system of H2O/MeOH (80/20 to 0/100) to afford 9 fractions (Fr1-Fr9). Subfraction Fr6 (695 mg) was separated into 9 subfractions (Fr6.1-Fr6.9) by chromatography over silica gel column with a gradient system of CHCl3/MeOH (100/0 to 70/30). 10 mg of compound **12** were obtained by precipitation of Fr6.9 in MeOH. Fraction Fr7 (780 mg) was subjected to CC over silica gel and eluted with petroleum ether/EtOAc (100/0 to 0/100) producing 10 subfractions (Fr7.1-Fr7.10). Fr7.4 (39 mg) was chromatographed on a silica gel CC eluting with petroleum ether/CHCl3 (100/0 to 15/85) to yield 4.3 mg of compound **13**. Fraction Fr9 (232 mg) was further chromatographed on a silica gel CC eluting with petroleum ether/CHCl3 (100/0 to 70/30) to yield 15 mg of pure compound **11**.

The *n*-butanol extract (7 g) was submitted to vacuum liquid chromatography VLC (50 mm × 50 mm; fractions of 100 ml) on RP-18 using H2O/MeOH (80:20 to 0:100) to obtain 15 fractions (Fr1–Fr15). Fr1 (5.53 g) was subjected to polyamide CC eluted with a gradient of H2O/MeOH (100:0 to 0:100) to obtain 16 subfractions (Fr1.1–Fr1.16). Fr1.5 (333 mg) was subjected to polyamide CC eluted with a gradient of toluene/MeOH to get 12 subfractions (Fr1.5.1–Fr1.5.12). Purification of Fr1.5.11 (57 mg) by HPLC column lead two compounds **3 (**3.4 mg) and **6**(2 mg). Further purification of Fr1.5.4 (36.1 mg) by TLC (SiO2) using CHCl3/MeOH/H2O (8:2:0.2) gave compound **8** (3.8 mg). Fr1.5.8 (26 mg) was chromatographed over polyamide CC using a gradient of toluene/MeOH (20:80 to 0:100) to yield four subfractions (Fr1.5.8.1–Fr1.5.8.4). Fr1.5.9 (32 mg) was also chromatographed over polyamide CC using a gradient of toluene/MeOH (10:90 to 0:100) as eluent to yield five subfractions (Fr1.5.9.1–Fr1.5.9.5). The mixed subfractions Fr1.5.9.3, Fr1.5.9.4 and Fr1.5.8.2 (41.6 mg) were chromatographed over SiO2 CC using CHCl3/MeOH (5:95 to 0:100) as eluent, to obtain six subfractions. The fifth subfraction (15 mg) was purified by HPLC to yield compounds **1 (**4.2 mg) and **5 (**2 mg). The mixed subfractions Fr1.7, Fr1.8, Fr1.9 and Fr1.10 (134.5 mg) were subjected to CC over silica gel eluting with CH2Cl2/acetone (100:0 to 0:100) to obtain 8subfractions (Fr1.7.1–Fr1.7.8). Fr1.7.5 was chromatographed on preparative TLC (RP-18) using MeOH/H2O (3:7) as eluent to give compound **7** (5 mg) as a mixture of 2*-*OH and 2*-*OH epimers in a ratio of 1:1 (estimated from the relative intensities of the proton signals). Subfraction Fr1.12 (117 mg) was submitted to Sephadex LH-20 CC eluted with CHCl3/MeOH (10%) to get 4subfractions (Fr1.12.1–Fr1.12.4). Fr1.12.1 was purified by HPLC column to produce compounds **2** (3.8 mg) and **4** (2.4 mg). Compound **9** (15 mg) was obtained by precipitation of Fr4 (60 mg) in MeOH. The residue of this fraction (Fr4) was subjected to CC over silica gel and eluted with gradient system CHCl3/MeOH (100:0 to 80:20), to give compound **10** (7 mg).

\* Corresponding author. E-mail: mbenkhaled@yahoo.fr

CHARACTERIZATION DATA FOR COMPOUNDS **3**-**10**



Quercetin-3-O-(2,6-**-L-dirhamnopyranosyl-**-D-glucopyranoside (**3**)

*Quercetin-3-O-(2,6--L-dirhamnopyranosyl--D-glucopyranoside (****3****):*1H NMR (500 MHz, MeOD, δ / ppm): 1.00 (3H, *d*, *J*= 5.6 Hz, H-6'''), 1.08 (3H, *d*, *J*= 5.9 Hz, H-6''''), 3.24 (1H, *t*, *J*= 9.4 Hz, H-4''''), 3.28 (1H, *m*, H-4''), 3.32 (1H, *m*, H-4'''), 3.33 (1H, *m*, H-5''), 3.38 (1H, *m*, Ha-6''), 3.43 (1H, *m*, H-5'''), 3.50 (1H, *dd*, *J1* = 9.4, *J2* = 3.4 Hz, H-3''''), 3.54 (1H, *t*, *J*= 8.8 Hz, H-3''), 3.58 (1H, *dd*, *J1* = 3.4, *J2* =1.6 Hz, H-2''''), 3.63 (1H, *dd*, *J1* = 8.8, *J2* = 7.8 Hz, H-2''), 3.81 (1H, *dd,J1* = 9.8, *J2* = 3.8 Hz, H-3'''), 3.83 (1H, *dd*, *J1* = 11.5, *J2* = 1.6 Hz, Hb-6''), 4,01 (1H, *dd*, *J1* = 3.8, *J2* = 1.6 Hz, H-2'''), 4.07 (1H, *m*, H-5''''), 4.50 (1H, *d*, *J*= 1.6 Hz, H-1''''), 5.22 (1H, *d*, *J*= 1.6 Hz, H-1'''), 5.59 (1H, *d*, *J*= 7.8 Hz, H-1''), 6.19 (1H, *d*, *J*= 2.1 Hz, H-6), 6.37 (1H, *d*, *J*= 2.1 Hz, H-8), 6.87 (1H, *d*, *J*= 8.1 Hz, H-5'), 7.60 (1H, *dd*, *J1*= 8.1, *J2* = 2.1 Hz, H-6'), 7.62 (1H, *d*, *J*= 2.1 Hz, H-2');13C NMR (125 MHz, MeOD, δ / ppm): 17.6 (CH3, C-6'''), 17.9 (CH3, C-6''''), 68.4 (CH2, C-6''), 69.9 (CH, C-5''''), 70.1 (CH, C-5'''), 72.0 (CH, C-4''), 72.3 (CH, C-3'''), 72.4 (CH, C-2''', C-3''''), 72.5 (CH, C-2''''), 74.0 (CH, C-4''''), 74.2 (CH, C-4'''), 77.3 (CH, C-5''), 79.1 (CH, C-3''), 80.2 (CH, C-2''), 94.8 (CH, C-8), 99.9 (CH, C-6), 100.6 (CH, C-1''), 102.4 (CH, C-1''''), 102.8 (CH, C-1'''), 106.1 (C, C-10), 116.2 (CH, C-5'), 117.5 (CH, C-2'), 123.6 (C, C-1'), 123.7 (C, C-7'), 134.6 (C, C-3), 146.1 (C, C-3'), 149.7 (C, C-4'), 158.6 (C, C-9), 159.1 (C, C-2), 163.3 (C, C-5), 165.8 (C, C-7), 179.5 (C, C-4). ESI-MS (*m/z*, (relative abundance, %)): 779 ((C33H40O20+Na)+, 100).



Calendoside III (**4**)

*Isorhamnetin-3-O--L-rhamnopyranosyl-(1–4)--D-glucopyranoside (Calendoside III) (****4****):* 1H NMR (500 MHz, MeOD, δ / ppm): 1.09 (3H, *d*, *J*= 6.2 Hz, H-6'''), 3.22 (1H, *t*, *J*= 9.8 Hz, H-4'''), 3.27 (1H, *dd*, *J1* = 9.3, *J2* = 7.3 Hz, H-4''), 3.40 (1H, *t*, *J*= 7.3 Hz, H-3''), 3.41 (1H, *ddd*, *J1*= 9.3, *J2*= 4.7, *J3* = 1.3 Hz, H-5''), 3.42 (1H, *m*, H-5'''), 3.46 (1H, *t*, *J*= 7.3 Hz, H-2''), 3,48 (1H, *dd*, *J1* = 9.8, *J2* = 3.4 Hz, H-3'''), 3.61 (1H, *dd*, *J1* = 3.4, *J2* =1.5 Hz, H-2'''), 3.80 (1H, *dd*, *J1* = 10.8, *J2* =1.3 Hz, Ha-6''), 3.92 (1H, *dd*, *J1* = 10.8, *J2* = 4.7 Hz, Hb-6''), 3.95 (3H, *s*, OMe), 4.52 (1H, *d*, *J*= 1.5 Hz, H-1'''), 5.25 (1H, *d*, *J*= 7.3 Hz, H-1''), 6.20 (1H, *d*, *J*= 2.1 Hz, H-6), 6.42 (1H, *d*, *J*= 2.1 Hz, H-8), 6.92 (1H, *d*, *J*= 8.6 Hz, H-5'), 7.64 (1H, *dd*, *J1* = 8.6, *J2* = 2.1 Hz, H-6'), 7.95 (1H, *d*, *J*= 2.1 Hz, H-2');13C NMR (125 MHz, MeOD, δ / ppm): 18.4 (CH3, C-6'''), 57.3 (CH3, 4'-OMe), 69.0 (CH2, C-6''), 70.3 (CH, C-5'''), 72.2 (CH, C-4''), 72.6 (CH, C-3'''), 72.8 (CH, C-2'''), 74.3 (CH, C-4'''), 76.4 (CH, C-2''), 78.7 (CH, C-3''), 95.4 (CH, C-8), 100.5 (CH, C-6), 103.1 (CH, C-1'''), 104.9 (CH, C-1''), 105.6 (C, C-10), 115.1 (CH, C-2'), 116.7 (CH, C-5'), 123.0 (C, C-1'), 124.5 (C, C-6'), 135.6 (C, C-3), 145.9 (C, C-3'), 148.9 (C, C-4'), 158.5 (C, C-9), 159.0 (C, C-2), 163.0 (C, C-5), 166.1 (C, C-7), 179.5 (C, C-4). ESI-MS (*m/z*, (relative abundance, %)): 779 ((C28H32O16+Na)+, 100).

**

Kaempferol-3-O-**-L-rhamnopyranosyl-(1–4)-**-D-glucopyranoside (**5**)

*Kaempferol-3-O--L-rhamnopyranosyl-(1–4)--D-glucopyranoside (****5****):* Yellow amorphous solid. 1H NMR (500 MHz, MeOD, δ / ppm): 0.95 (3H, *d*, *J*= 6.4 Hz, H-6'''), 3.20 (1H, *ddd*, *J1* = 9.1, *J2* = 6.2, *J3* = 2.2 Hz, H-5''), 3.28 (1H, *t*, *J*= 9.1 Hz, H-4''), 3.33 (1H, *t*, *J*= 9.2 Hz, H-4'''), 3.50 (1H, *dd*, *J1* = 12.0, *J2* = 6.2 Hz, Ha-6''), 3.55 (1H, *t*, *J*= 9.1 Hz, H-3''), 3.61 (1H, *dd* , *J1*= 9.1, *J2* = 7.7 Hz, H-2''), 3.72 (1H, *dd*, *J1* = 12.0, *J2* = 2.2 Hz, Hb-6''), 3.77 (1H, *dd*, *J1* = 9.2, *J2*= 3.4 Hz, H-3'''), 3.99 (1H, *dd*, *J1* = 3.4, *J2* = 1.6 Hz, H-2'''), 4,02 (1H, *dq*, *J1* = 9.2, *J2* = 6.4 Hz, H-5'''), 5.23 (1H, *d*, *J*= 1.6 Hz, H-1'''), 5.73 (1H, *d*, *J*= 7.7 Hz, H-1''), 6.15 (1H, *brs*, H-6), 6.34 (1H, *brs*, H-8), 6.88 (2H, *d*, *J*= 9.1 Hz, H-3', H-5'), 8.04 (2H, *d*, *J*= 9.1 Hz, H-2', H-6');13C NMR (125 MHz, MeOD, δ / ppm): 17.7 (CH3, C-6'''), 62.8 (CH2, C-6''), 70.1 (CH, C-5'''), 71.9 (CH, C-4''), 72.4 (CH, C-3'''), 72.6 (CH, C-2'''), 74.2 (CH, C-4'''), 79.2 (CH, C-3''), 80.3 (CH, C-2''), 94.6 (CH, C-8), 100.3 (CH, C-1''), 101.0 (CH, C-6), 102.8 (CH, C-1'''), 105.9 (C, C-10), 116.3 (CH, C-3', C-5'), 123.1 (C, C-1'), 132.2 (CH, C-2', C-6'), 134.4 (C, C-3), 158.4 (C, C-9), 158.5 (C, C-2), 161.6 (C, C-4'), 163.2 (C, C-5), 165.6 (C, C-7), 179.4 (C, C-4). ESI-MS (*m/z*, (relative abundance, %)): 617 ((C27H30O15+Na)+, 100).

**

3',5'-di-*C*--D-glucopyranosylphloretin (**6**)

*3',5'-di-C--D-glucopyranosylphloretin (****6****):* Yellow solid. [*α*] D = + 83.6 (*c* = 1.0 g mL-1, MeOH). 1H NMR (500 MHz, MeOD, δ / ppm): 2.86 (2H, *m*, H-**), 3.34 (2H, *m*, H-**), 3.42 (2H, *m*, H-5'', H-5'''), 3.51 (2H, *t*, *J*= 9.4 Hz, H-3'', H-3'''), 3.53 (2H, *t*, *J*= 9.4 Hz, H-4'', H-4'''), 3.62 (2H, *t*, *J*= 9.4 Hz, H-2'', H-2'''), 3.82 (2H, *dd*, *J1* = 12.5, *J2*= 2.0 Hz, Ha-6'', Ha-6'''), 3.86 (2H, *dd*, *J1*= 12.5, *J2* = 2.0 Hz, Hb-6'', Hb-6'''), 4.94 (2H, *d*, *J*= 9.4 Hz, H-1'', H-1'''), 6.67 (2H, *d*, *J*= 8.5 Hz, H-3, H-5), 7.04 (1H, *d*, *J*= 8.5 Hz, H-2, H-6);13C NMR (125 MHz, MeOD, δ / ppm): 31.3 (CH2, C-**), 48.0 (CH2, C-**), 62.1 (CH2, C-6'', C-6'''), 71.2 (CH, C-4'', C-4'''), 74.3 (CH, C-2'', C-2'''), 76.9 (CH, C-1'', C-1'''), 79.3 (CH, C-3'', C-3'''), 82.9 (CH, C-5'', C-5'''), 104.6 (C, C-3', C-5'), 106.2 (C, C-1'), 116.3 (CH, C-3, C-5), 130.6 (CH, C-2, C-6), 134.1 (C, C-1), 156.6 (C, C-4), 162.2 (C, C-2', C-6'), 163.1 (C, C-4'), 207.2 (C, C=O). ESI-MS (*m/z*, (relative abundance, %)): 597 ((C27H34O15-H)-, 100).

**

Hovetrichoside C (**7**)

*Hovetrichoside C (****7****):* Amorphous powder. [*α*]20D = -35 (*c* = 0.02 g mL-1, MeOH). 1H NMR (500 MHz, DMSO-*d6*, δ / ppm): 2.90 (2H, *m*, H-1'), 3.17 (1H, *m*, H-4''), 3.19 (1H, *m*, H-3''), 3.24 (1H, *m*, H-2''), 3.25 (1H, *m*, H-5''), 3.47 (1H, *m*, Ha-6''), 3.61 (1H, *m*, Hb-6''), 4.90 (1H, *d*, *J*= 8.2 Hz, H-1''), 5.93 (1H, *d*, *J*= 1.8 Hz, H-7), 6.00 (1H, *d*, *J*= 1.8 Hz, H-5), 6.55 (2H, *d*, *J*= 7.1 Hz, H-4', H-6'), 6.92 (2H, *d*, *J*= 7.1 Hz, H-3', H-7');13C NMR (125 MHz, DMSO-*d6*, δ / ppm): 40.4 (CH2, C-1'), 60.4 (CH2, C-6''), 69.3 (CH, C-4''), 72.9 (CH, C-2''), 76.7 (CH, C-3''), 77.2 (CH, C-5''), 91.5 (CH, C-7), 95.2 (CH, C-5), 99.4 (CH, C-1''), 101.9 (C, C-9), 105.5 (C, C-2), 114.7 (CH, C-4', C-6'), 124.1 (C, C-2'), 131.3 (CH, C-3', C-7'), 155.9 (C, C-5'), 156.7 (C, C-4), 168.4 (C, C-6), 171.9 (C, C-8), 192.4 (C, C-3). ESI-MS (*m/z*, (relative abundance, %)): 449 ((C21H22O11-H)-, 100).

*(****7'****)*: 1H NMR (500 MHz, DMSO-*d6*, δ / ppm): 2.90 (2H, *m*, H-1'), 3.17 (1H, *m*, H-4''), 3.19 (1H, *m*, H-3''), 3.24 (1H, *m*, H-2''), 3.25 (1H, *m*, H-5''), 3.47 (1H, *m*, Ha-6''), 3.61 (1H, *m*, Hb-6''), 4.90 (1H, *d*, *J*= 8.2 Hz, H-1''), 5.93 (1H, *d*, *J*= 1.8 Hz, H-7), 6.05 (1H, *d*, *J*= 1.8 Hz, H-5), 6.55 (2H, *d*, *J*= 7.1 Hz, H-4', H-6'), 6.92 (2H, *d*, *J*= 7.1 Hz, H-3', H-7');13C NMR (125 MHz, DMSO-*d6*, δ / ppm): 40.4 (CH2, C-1'), 60.3 (CH2, C-6''), 69.2 (CH, C-4''), 73.0 (CH, C-2''), 76.7 (CH, C-3''), 77.1 (CH, C-5''), 91.7 (CH, C-7), 95.7 (CH, C-5), 99.2 (CH, C-1''), 101.9 (C, C-9), 105.5 (C, C-2), 114.7 (CH, C-4', C-6'), 124.1 (C, C-2'), 131.3 (CH, C-3', C-7'), 155.9 (C, C-5'), 156.7 (C, C-4), 168.4 (C, C-6), 171.9 (C, C-8), 192.7 (C, C-3).



Isolariciresinol 9'-O--D-glucopyranoside (**8**)

*Isolariciresinol 9'-O--D-glucopyranoside(****8****)*. White amorphous powder. [*α*] D = + 16 (*c* = 0.9 g mL-1, MeOH /CH2Cl2 (1/0.5)). 1H NMR (500 MHz, DMSO-*d6*, δ / ppm): 1.72 (1H, *m*, H-8'), 1,91 (1H, *m*, H-8), 2.72 (2H, *d*, *J*= 8.0 Hz, H-7), 2.96 (1H, *m*, Ha-9'), 2.97 (1H, *t*, *J*= 7.8 Hz, H-2''), 3.01 (1H, *ddd*, *J1*= 9.3, *J*2 = 4.7, *J3 =* 2.6 Hz, H-5''), 3.03 (1H, *dd*, *J1* = 9.3, *J*2 = 7.8 Hz, H-4''), 3.13 (1H, *t*, *J* = 7.8 Hz, H-3''), 3.41 (1H, *dd*, *J*= 11.7; 2.6 Hz, Ha-6''), 3.45 (1H, *m*, Ha-9); 3.57 (1H, *m*, Hb-9), 3.63 (1H, *dd*, *J1* = 11.7, *J*2 = 4.7 Hz, Hb-6''), 3.71 (6H, *s*, 5-OMe/3'-OMe), 3.90 (1H, *dd*, *J1* = 9.8, *J*2 = 1.9 Hz, Hb-9'), 3.95 (1H, *d*, *J* = 7.8 Hz, H-1''), 4.03 (1H, *d*, *J* = 10.7 Hz, H-7'), 6.08 (1H, *brs*, H-3), 6.50 (1H, *dd*, *J* = 8.2; 1.8 Hz, H-6'), 6.61 (1H, *brs*, H-6 ), 6.68 (1H, *d*, *J* = 8.2 Hz, H-5'), 6.80 (1H, *d*, *J* = 1.8 Hz, H-2');13C NMR (125 MHz, DMSO-*d6*, δ / ppm): 32.5 (CH2, C-7), 37.5 (CH, C-8), 44.1 (CH, C-8'), 45.5 (CH, C-7'), 55.5 (5-OMe), 55.6 (3'-OMe), 61.0 (CH2, C-6''), 62.8 (CH2, C-9), 67.6 (CH2, C-9'), 70.0 (CH, C-4''), 73.3 (CH, C-2''), 76.7 (CH, C-5''), 76.8 (CH, C-3''),104.1 (CH, C-1''), 111.8 (CH, C-6), 113.9 (CH, C-2'),115.5 (CH, C-5'), 116.2 (CH, C-3),121.1 (CH, C-6'), 127.0 (C, C-1), 132.7 (C, C-2), 136.9 (C, C-1'), 144.0 (C, C-4), 144.5 (C, C-5, C-4'), 147.1 (C, C-3'). ESI-MS (*m/z*, (relative abundance, %)): 545 ((C26H34O11+Na)+, 100).



Soyasaponin I (**9**)

*Soyasaponin I(****9****)*. White amorphous solid. [*α*]20 D = - 12 (*c* = 0.9 g mL-1, MeOH). 1H NMR (500 MHz, DMSO-*d6*, δ / ppm): 0.83 (3H, *s*, H-28), 0.92 (3H, *s*, H-30), 0.93 (1H, *m*, H-5), 0.95 (1H, *m*, H-19a), 0.98 (3H, *s*, H-26), 1.01 (1H, *m*, Ha-1), 1.03 (3H, *s*, H-29), 1.04 (2H, *m*, Ha-2), 1.13 (3H, *s*, H-27), 1.24 (3H, *s*, H-23), 1.27 (3H, *d*, *J*= 8.6 Hz, H-6'''), 1.29 (2H, *m*, Ha-16, Hb-16), 1.32 (1H, *m*, H-21b), 1.36 (2H, *m*, Ha-6), 1.44 (1H, *m*, Ha-21), 1.42 (1H, *m*, Ha-7), 1.54 (1H, *m*, Hb-7), 1.57 (1H, *m*, H-9), 1.63 (2H, *m*, Hb-6), 1.65 (1H, *m*, Hb-1), 1.76 (2H, *m*, Hb-2), 1.75 (1H, *m*, Hb-19), 1.86 (2H, *m*, Ha-15, Hb-15), 1.87 (2H, *m*, Ha-11, Hb-11), 2.07 (1H, *d*, *J* = 14.7 Hz, H-18), 3.22 (1H, *d*, *J* = 11.3 Hz, Ha-24), 3.37 (1H, *dd*, *J1*= 5.1, *J*2 = 3.5 Hz, H-22), 3.40 (1H, *dd*, *J1* = 10.3, *J*2 = 3.5 Hz, H-3), 3.42 (1H, *t*, *J* = 9.6 Hz, H-4'''), 3.46 (1H, *t*, *J* = 9.4 Hz, H-4'), 3.48 (1H, *m*, H-5''), 3.54 (1H, *dd*, *J1* = 9.5; *J*2 = 3.1 Hz, H-3''), 3.61 (1H, *d*, *J* = 7.9 Hz, H-5'), 3.62 (1H, *dd*, *J1* = 9.5; *J*2 = 7.5 Hz, H-2''), 3.64 (1H, *dd*, *J1* = 9.4, *J2* = 7.9 Hz, H-3'), 3.72 (1H, *dd*, *J1*= 9.6, *J2* = 3.5 Hz, H-3'''), 3.72 (1H, *m*, Ha-6''/Hb-6''), 3.74 (1H, *dl*, *J* = 3.1 Hz, H-4''), 3.76 (1H, *d*, *J* = 7.9 Hz, H-2'), 3.92 (1H, *dd*, *J1*= 3.5; *J2* = 1.9 Hz, H-2'''), 4.12 (1H, *m*, H-5'''), 4.13 (1H, *d*, *J* = 11.3 Hz, Hb-24), 4.45 (1H, *d*, *J* = 7.9 Hz, H-1'), 4.87 (1H, *d*, *J* = 7.5 Hz, H-1''), 5.14 (1H, *d*, *J* = 1.9 Hz, H-1'''), 5.25 (2H, *t*, *J* = 3.3 Hz, H-12),13C NMR (125 MHz, DMSO-*d6*, δ / ppm): 16.6 (CH3, C-25), 17.7 (CH3, C-26), 18.5 (CH3, C-6'''), 19.5 (CH2, C-6), 20.6 (CH3, C-28), 23.6 (CH3, C-23), 25.0 (CH2, C-11), 25.6 (CH3, C-27), 27.0 (CH2, C-2), 27.3 (CH2, C-15), 29.2 (CH3, C-29), 30.0 (CH2, C-16), 31.5 (C, C-20), 32.7 (CH3, C-30), 34.5 (CH2, C-7), 37.6 (C, C-10), 38.7 (C, C-17), 39.8 (CH2, C-1), 40.9 (C, C-8), 42.3 (CH2, C-21), 43.5 (C, C-14),44.9 (C, C-4), 46.9 (CH, C-18), 47.6 (CH2, C-19), 47.9 (CH, C-9), 57.5(CH, C-5), 62.3 (CH2, C-6''), 64.5 (CH2, C-24), 69.6 (CH, C-5'''), 71.7 (CH, C-3'''), 72.3 (CH, C-4'', C-2'''), 74.3 (CH, C-4'), 74.4 (CH, C-4'''), 76.4 (CH, C-3''), 76.5 (CH, C-5''), 77.1 (CH, C-22), 77.3 (CH, C-2', C-5'), 78.2 (CH, C-3'), 78.5 (CH, C2''), 92.7 (CH, C-3), 102.4 (CH, C-1''), 102.5 (CH, C-1'''), 105.7 (CH, C-1'), 123.8 (CH, C-12), 145.4 (C, C13), 175.6 (C, COOH). ESI-MS (*m/z*, (relativeabundance, %)): 965 ((C48H78O18+Na)+, 100).



Dehydrosoyasaponin I (**10**)

*Dehydrosoyasaponin I (****10****):* White amorphoussolid. [*α*] D = -15.2 (*c* = 0.23 g mL-1, MeOH). 1H NMR (600 MHz, CD3OD, δ / ppm): 0.87 (3H, *s*, H-30), 0.92 (3H, *s*, H-25), 0.96 (1H, *m*, H-5), 1.00 (3H, *s*, H-26), 1.01 (3H, *s*, H-28), 1.03-1.66 (1H, *m*, H-1), 1.03 (3H, *s*, H-29), 1.12-2.17 (2H, *m*, H-16), 1.29 (3H, *s*, H-23), 1.30 (3H, *s*, H-27), 1.30 (3H, *d*, *J*= 8.6 Hz, H-6'''), 1.33-1.85 (2H, *m*, H-15), 1.34 (1H, *m*, H-19a), 1.39-1.66 (2H, *m*, H-6), 1.40-1.68 (1H, *m*, H-7), 1.64 (1H, *m*, H-9), 1.8-1.13 (2H, *m*, H-2), 1.92 (2H, *m*, Ha-11, Hb-11), 1.99-2.59 (1H, *m*, H-21), 2.23 (1H, *t,J* = 13,8 Hz, Hb-19), 2.37 (1H, *dd*, *J1*= 13.8, *J2* = 3.8 Hz, H-18), 3.23 (1H, *d*, *J* = 11.5 Hz, Ha-24), 3.42 (1H, *dd*, *J1* = 10.3, *J2* = 4.5 Hz, H-3), 3.42 (1H, *t*, *J*= 9.6 Hz, H-4'''), 3.46 (1H, *t,J*= 9.2 Hz, H-4'), 3.51 (1H, *m*, H-5''), 3.56 (1H, *dd*, *J1* = 9.6; *J2* = 3.5 Hz, H-3''), 3.61 (1H, *d*, *J* = 9.2 Hz, H-5'), 3.62 (1H, *dd*, *J1* = 9.2, *J2* = 8.3 Hz, H-3'), 3.66 (1H, *dd*, *J1* = 9.6; *J2* = 7.5 Hz, H-2''), 3.72 (1H, *m*, Hb-6''), 3.73 (1H, *nd*, H-3'''), 3.74 (1H, *nd*, H-4''), 3.76 (1H, *m*, Ha-6''), 3.78 (1H, *d*, *J*= 8.3 Hz, H-2'), 3.94 (1H, *dd*, *J1* = 3.3; *J2* = 1.6 Hz, H-2'''), 4.12 (1H, *m*, H-5'''), 4.16 (1H, *d*, *J*= 11.5 Hz, Hb-24), 4.48 (1H, *d*, *J*= 8.3 Hz, H-1'), 4.90 (1H, *d*, *J*= 7.5 Hz, H-1''), 5.15 (1H, *d*, *J*= 1.6 Hz, H-1'''), 5.35 (2H, *t*, *J*= 3.5 Hz, H-12);13C NMR (150 MHz, CD3OD, δ / ppm): 14.9 (CH3, C-25), 15.9 (CH3, C-26), 16.9 (CH3, C-27, C-6'''), 18.0 (CH2, C-6), 19.7 (CH3, C-28), 22.0 (CH3, C-23), 23.5 (CH2, C-11), 24.2 (CH3, C-30), 24.8 (CH2, C-2), 25.7 (CH2, C-15), 27.0 (CH2, C-16), 30.8 (CH3, C-29), 32.6 (CH2, C-7), 33.7 (C, C-20), 36.1 (C, C-10), 38.3 (CH2, C-1), 39.4 (C, C-8), 41.6 (C, C-14), 43.3 (C, C-4), 46.2 (CH2, C-19), 47.6 (CH, C-18), 47.3 (CH, C-9), 48.0 (C, C-17), 50.3 (CH2, C-21), 55.9 (CH, C-5), 60.8 (CH2, C-6''), 62.9 (CH2, C-24), 68.1 (CH, C-5'''), 70.3 (CH, C-3'''), 70.8 (CH, C-4'', C-2'''), 72.8 (CH, C-4', C-4'''), 74.9 (CH, C-3''), 75.7 (CH, C-5''), 75.8 (CH, C-2', C-5'), 76.9 (CH, C-3'), 77.8 (CH, C2''), 91.0 (CH, C-3), 100.7 (CH, C-1''), 100.9 (CH, C-1'''), 104.1 (CH, C-1'), 123.7 (CH, C-12), 141.4 (C, C13), 175.6 (C, COOH), 218.3 (CH, C-22). ESI-MS (*m/z*, (relative abundance, %)): 963 ((C48H76O18+Na)+, 100).

DPPH RADICAL SCAVENGING ACTIVITY ASSAY

The free radical scavenging activity of *n*-butanol extract of *Astragalusmospessulanus* L. was measured *in vitro* by 2,2’-Diphenyl-1-picrylhydrazyl (DPPH) according to the procedure described by (Saeed *et al.* 2012).The stocksolutionwaspreparedby dissolving 2.5 mg DPPH with 100 ml methanol and stored at 20°C until required. The working solution was obtained by diluting DPPH solution with methanol to attain an absorbance of about 0.98±0.02 at 517 nm using the spectrophotometer. A 3 ml aliquot of thissolutionwas mixed with 100μl of the sample at various concentrations. The reaction mixture was shaken well and incubated in the dark for 30 min at room temperature. Then the absorbance was taken at 517nm. Ascorbic acid was used as reference compound. The scavenging activity was estimated based on the percentage of DPPH radical scavenged as the following equation:

$Scavenging activity\left(\%\right)=\left[\frac{Acontrol-A sample}{A control}\right]×100$(1)

The antiradical activity of tested extract is expressed as a relative or absolute decrease of concentration of DPPH or as *IC50* (concentration of extract decreasing the absorbance of the DPPH solution by 50 %).

REFERENCE

N. Saeed,M. R. Khan,M.Shabbir,*The official Journal of the International Society for Complementary Medicine Research (ISCMR).***12** (2012) 221



Fig. S1. Evolution of DPPH radical scavenging activity with concentration of ascorbic acid



Fig.S2.Evolution of DPPH radical scavenging activity with *n*-BuOH extract concentration of *Astragalus monspessulanus*.The Data was represented as Mean (n=3)